A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Sponsor: Adaptimmune
Enrolling: Male and Female Patients
IRB Number: AAAS4184
U.S. Govt. ID: NCT04044768
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if an investigational drug, called ADP-A2M4, is safe and how well it works in attacking Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) cancer cells. The study involves taking certain types of immune cells from the blood, called T cells, and changing them in a laboratory before putting them back into the bloodstream, with the aim of helping them to attack and kill cancer cells. The goal is to learn if these genetically changed T cells are safe and work to kill these cancer cell types.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Are you/your child between the ages of 16-75? Yes No
Have you/your child been diagnosed with advanced synovial sarcoma or myxoid liposarcoma/myxoid round cell liposarcoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator